-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-outcomes_methods.pdf
July 01, 2012 - testing process poses potential harms, including
allergic reaction to the intravenous contrast material, renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_research-protocol.pdf
March 09, 2010 - Privigen 10%
Vivaglobin
Interaction with
activating Fc
receptors; biologic
No
Hepatitis; acute renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/lung-cancer-staging_research-protocol.pdf
December 08, 2014 - In
addition, some patients cannot receive iodinated contrast material due to renal
insufficiency, limiting … previously noted, performance
of various imaging modalities may be impacted by comorbidities such renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
October 06, 2006 - Procedural
non-fatal
MI %*
Freedom
from
Stroke
%
NI
%**
CHF
%
Respiratory
failurea %
Renal … Procedural
non-fatal
MI %*
Freedom
from
Stroke
%
NI
%**
CHF
%
Respiratory
failurea %
Renal … ο Calculated N
Bleeding requiring a transfusion ο Calculated N
Renal … outcomes: We are interested in CHF, stroke, respiratory failure or other pulmonary complications, renal
-
effectivehealthcare.ahrq.gov/sites/default/files/coronary-artery-disease-testing_executive.pdf
March 01, 2011 - events
• Dysrhythmia
Ultimate Health Outcomes
Adverse Effects or Harms of Testing
Procedural harms: renal … interest for both the
index test and any subsequent downstream testing included
harms of testing (e.g., renal … groups—procedural stroke (0.02% vs.
0.04%), major bleeding (0.1% in both groups), anaphylaxis
or renal … There were no cases of post-test
renal dysfunction (low strength of evidence). … unstable angina; or a major
procedural complication, such as stroke, major bleeding,
anaphylaxis, or renal
-
effectivehealthcare.ahrq.gov/sites/default/files/lung-cancer-staging_executive.pdf
April 01, 2016 - In
addition, some patients cannot receive iodinated contrast
material due to allergy or renal insufficiency … patient subgroups, performance of various
imaging modalities may be affected by comorbidities such
renal
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pdf/epc-year-in-review-2020.pdf
January 01, 2020 - End-stage Renal Disease in the Medicare Population: Frequency and Duration of Hemodialysis and Quality
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
October 01, 2011 - observational studies found acetaminophen associated
with modest increases in blood pressure or higher risk of renal … Hypertension is the second leading
cause of kidney failure or End Stage Renal
Disease in the United … Effects of NSAIDs on HTN and renal function are
reviewed starting on page 66, line 7.
Rosa L.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/opioids-oa-protocol.pdf
June 29, 2019 - of potential risk factors for harm from opioids, including
cognitive impairment, altered hepatic or renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-brief1-care-coordination.pdf
April 01, 2021 - or 13
15 6 and 14
16 Medicare/
17 (medicare or disabled or disabilit* or kidney or renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief1-care-coordination.pdf
April 01, 2021 - or 13
15 6 and 14
16 Medicare/
17 (medicare or disabled or disabilit* or kidney or renal
-
effectivehealthcare.ahrq.gov/sites/default/files/ch_3-user-guide-to-ocer_130129.pdf
September 21, 2012 - variables (e.g., timing after
stroke, stable or unstable angina); (3) comorbidities
(e.g., presence of renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse-drug-therapy_executive.pdf
January 27, 2012 - Acamprosate is contraindicated
for people with severe renal impairment and requires
dose adjustments … for moderate renal impairment.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization-cost_research.pdf
January 01, 2011 - Administration (FDA) has
labeled peginterferon alfa-2a for use in hepatitis,
off-label uses include renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cystic-fibrosis-hgh_research-protocol.pdf
August 22, 2008 - growth hormone deficiency, idiopathic short
stature, Turner syndrome, Prader-Willi Syndrome, chronic renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-family-engagement-protocol.pdf
December 31, 2019 - Abbreviations: DM=diabetes, HTN=hypertension, IT=information technology, ER=emergency room; ESRD=end stage renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-insulin_executive.pdf
September 01, 2008 - All
trials either excluded patients with cardiac, renal, or
hepatic disease or did not report whether
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_disposition-comments.pdf
September 01, 2011 - basal
amount of drug without pharmacologic consultation regarding volume
distribution, body mass and renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/skin-cancer_research-protocol.pdf
August 10, 2016 - limited life expectancy (e.g., the very elderly, those with
terminal cancer, those with end stage renal
-
effectivehealthcare.ahrq.gov/sites/default/files/mcda_webinar_transcript2.pdf
August 27, 2012 - The gain for going from five
months to ten months in progression free survival in renal
cell carcinoma … specific question for you, Reed, is how
do you manage to get patient input on things like treatment
for renal